Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643592 | 0.85 | LMNA (0.56) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL26142063 | 0.82 | MME (0.39) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL6695804 | 0.82 | GLRA1 (0.36) | LMNAOR51E2GLRA1SLC6A9 | |
| SCHEMBL20599906 | 0.79 | PTPN1 (0.35) | LDHASRRLMNATDP1ALDH1A1 | |
| SCHEMBL3132707 | 0.76 | MAPK1 (0.55) | KDM4EALDH1A1MAPTECE1 | |
| SCHEMBL1742036 | 0.76 | — | — | |
| SCHEMBL26292894 | 0.76 | TDP1 (0.39) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL7044031 | 0.76 | MME (0.41) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL16267385 | 0.74 | MME (0.39) | LMNATDP1CNR1ADRA1AKDM4E | |
| SCHEMBL3049168 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569132-A1 | Improvements in radiolabelling | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1993-11-10 | — | — | EP | claimed |
| JP-6065169-A | — | — | None | — | — | JP | disclosed |
| US-20250287937-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-12391799-B2 | Peptoid polymers and methods of use | X-THERMA, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12137682-B2 | Compositions and methods for reducing ice crystal formation | X-THERMA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-110769689-B | Novel supercooling method for preserving biological samples | 先时迈纳米生物科技股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3609906-B1 | NOVEL PEPTOID POLYMERS AND METHODS OF USE | X THERMA INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240084074-A1 | NOVEL PEPTOID POLYMERS AND METHODS OF USE | X-THERMA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20230292741-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | X-THERMA, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230292741-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | X-THERMA, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2007054288-A1 | REPAIR FILM AND USE THEREOF | BASF COATINGS AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054289-A2 | AQUEOUS POWDER DISPERSION, WHICH CAN BE CURED BY RADICAL POLYMERIZATION, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | BASF COATINGS AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2005009963-A1 | CHELANTS AND MACROCYCLIC METAL COMPLEX RADIOPHARMACEUTICALS TIHEREOF | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050008575-A1 | Chelants and macrocyclic metal complex radiopharmaceuticals thereof | LANTHEUS MEDICAL IMAGING, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050010038-A1 | Chelants and macrocyclic metal complex radiopharmaceuticals thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-01-13 | — | — | US | disclosed |
| US-6346547-B1 | TREATING ATHEROSCLEROSIS, RESTENOSIS AND STROKE | CHECKPOINT, GENETICS, INC. | 2002-02-12 | — | — | US | disclosed |
| EP-0569132-B1 | Improvements in radiolabelling | ANORMED INC (CA) | 2000-03-01 | — | — | EP | disclosed |
| US-5350837-A | Complexes with 99m Tc suitable for radiolabelling monoclonal antibodies or other macro molecules | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1994-09-27 | — | — | US | disclosed |
| JP-H0665169-A | IMPROVED RADIOLABELLING | JOHNSON MATTHEY PLC | 1994-03-08 | — | — | JP | disclosed |
| EP-0569132-A1 | Improvements in radiolabelling | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250287937-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | CUTA, IAPP, CRYAA | LDHA 3237/4885SRR 2586/4885LMNA 670/4885 |
| US-12391799-B2 | Peptoid polymers and methods of use | IAPP, CUTA, VIP | LDHA 3263/4885SRR 2870/4885LMNA 951/4885 |
| US-20240084074-A1 | NOVEL PEPTOID POLYMERS AND METHODS OF USE | CUTA, IAPP, CRYAA | LDHA 3573/4885SRR 2712/4885LMNA 1046/4885 |
| US-12137682-B2 | Compositions and methods for reducing ice crystal formation | CUTA, IAPP, CRYAA | LDHA 3237/4885SRR 2586/4885LMNA 670/4885 |
| US-20050008575-A1 | Chelants and macrocyclic metal complex radiopharmaceuticals thereof | TFRC, HLCS, CLTC | LDHA 3253/4885SRR 1175/4885LMNA 3591/4885 |
| US-20050010038-A1 | Chelants and macrocyclic metal complex radiopharmaceuticals thereof | TFRC, HLCS, CLTC | LDHA 3253/4885SRR 1175/4885LMNA 3591/4885 |
| US-20230292741-A1 | NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES | PPIG, AQP3, AQP1 | LDHA 2665/4885SRR 2955/4885LMNA 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.